Answers are grounded in this paper and cite their sources.
Evaluation reveals potent activity against tuberculosis in vitro, suggesting a new drug development platform.
A novel series of 4-[(aryloylhydrazineylidene)methyl]-N-phenylbenzamides was designed, synthesized, and evaluated as potential antitubercular agents. The compounds were obtained through a two-step synthesis from pyridine-4-carbohydrazide or 3,5-dinitrobenzohydrazide precursors, using 4-formylbenzoic acid as a molecular linker and various 4-substituted anilines to fine-tune lipophilicity and electronic properties. All derivatives were tested in vitro against Mycobacterium tuberculosis (Mtb), M. avium, and M. kansasii, including multidrug-resistant clinical isolates. Several amides displayed potent and selective activity against Mtb, with minimum inhibitory concentrations ≤0.03 μM, surpassing isoniazid (INH). Structure-activity relationship analysis revealed that INH-based derivatives generally outperformed their 3,5-dinitrobenzohydrazide counterparts and that halogen or electron-donating substituents enhanced potency. Mode-of-action studies using metabolic labeling and enzyme overexpression experiments indicated that the most active compounds interfere with mycolic acid biosynthesis, consistent with an InhA-related mechanism. Cytotoxicity evaluation in rat precision-cut liver slices confirmed good tolerance. Overall, these benzamide-hydrazone hybrids represent a promising chemotype, offering a valuable platform for further optimization toward next-generation antitubercular drug candidates.
No takes yet. Share an insight, caveat, or question.
Pflégr et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: